HPC3
MCID: PRS134
MIFTS: 20

Prostate Cancer, Hereditary, 3 (HPC3)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 3

MalaCards integrated aliases for Prostate Cancer, Hereditary, 3:

Name: Prostate Cancer, Hereditary, 3 57 13 70
Prostate Cancer, Susceptibility to, 3 57
Prostate Cancer 3 57
Hpc3 57

Classifications:



External Ids:

OMIM® 57 608656
MedGen 41 C1837595
UMLS 70 C1837595

Summaries for Prostate Cancer, Hereditary, 3

MalaCards based summary : Prostate Cancer, Hereditary, 3, also known as prostate cancer, susceptibility to, 3, is related to prostate cancer and prostatic hyperplasia, benign. An important gene associated with Prostate Cancer, Hereditary, 3 is HPC3 (Prostate Cancer, Hereditary, 3). Affiliated tissues include prostate, bone and testis.

More information from OMIM: 608656

Related Diseases for Prostate Cancer, Hereditary, 3

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 3:



Diseases related to Prostate Cancer, Hereditary, 3

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 3

Clinical features from OMIM®:

608656 (Updated 05-Apr-2021)

Drugs & Therapeutics for Prostate Cancer, Hereditary, 3

Search Clinical Trials , NIH Clinical Center for Prostate Cancer, Hereditary, 3

Genetic Tests for Prostate Cancer, Hereditary, 3

Anatomical Context for Prostate Cancer, Hereditary, 3

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 3:

40
Prostate, Bone, Testis, Endothelial

Publications for Prostate Cancer, Hereditary, 3

Articles related to Prostate Cancer, Hereditary, 3:

(show top 50) (show all 74)
# Title Authors PMID Year
1
Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. 57
11409871 2001
2
Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer. 57
11179028 2001
3
Evidence for a prostate cancer-susceptibility locus on chromosome 20. 57
10820130 2000
4
Isoleucine with secondary sulfonamide functionality as anticancer, antibacterial and antifungal agents. 61
33704017 2021
5
Identifying and Addressing Health Disparities among African American Men with Prostate Cancer: a Systematic Literature Review. 61
33474714 2021
6
Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study. 61
33037765 2020
7
Pelvic radiation therapy as a potential risk factor for ischemic colitis complicating abdominal aortic reconstruction. 61
32715182 2020
8
On-chip RT-LAMP and colorimetric detection of the prostate cancer 3 biomarker with an integrated thermal and imaging box. 61
31816706 2020
9
Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. 61
31077523 2019
10
Correlation of mRNA-PCA3 urine levels with the new grading system in prostate cancer. 61
30583827 2019
11
Design, Synthesis and Biological Evaluation of 4-Aryl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one Derivatives as a PI3Kα Inhibitor. 61
31155575 2019
12
Palladium nanoparticle-decorated 2-D graphene oxide for effective photodynamic and photothermal therapy of prostate solid tumors. 61
29843117 2018
13
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. 61
28867562 2018
14
Diffusion Kurtosis Imaging Helps to Predict Upgrading in Biopsy-Proven Prostate Cancer With a Gleason Score of 6. 61
28834443 2017
15
Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies. 61
28797620 2017
16
Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCε gene-mediated Notch1/Hes and androgen receptor signaling pathway. 61
28485785 2017
17
Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies. 61
28380027 2017
18
Prostate-Specific Membrane Antigen Uptake in Small Cleaved B-Cell Follicular Non-Hodgkin Lymphoma. 61
27749416 2016
19
Prostate-Specific Membrane Antigen (PSMA) Avid Pancreatic Neuroendocrine Tumor. 61
27454602 2016
20
Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. 61
27140073 2016
21
Choosing Wisely® in Preventive Medicine: The American College of Preventive Medicine's Top 5 List of Recommendations. 61
27155735 2016
22
Bilateral Choroidal Metastases from Prostate Cancer revealed in a patient under Abiraterone - Fourteen years after diagnosis. 61
27250892 2016
23
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells. 61
26976978 2016
24
[Prostate cancer incidence and mortality trends in France from 1980 to 2011]. 61
26043950 2015
25
Photobleaching of fluorescein as a probe for oxidative stress in single cells. 61
25218588 2014
26
Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells. 61
24739220 2014
27
Molecular effects of bioactive fraction of Curcuma mangga (DLBS4847) as a downregulator of 5α-reductase activity pathways in prostatic epithelial cells. 61
24944518 2014
28
Detection and quantification of enzymatically active prostate-specific antigen in vivo. 61
23933968 2013
29
A comparison of US and Australian men's values and preferences for PSA screening. 61
24093428 2013
30
[Safety and effectiveness of testicular prosthesis implantation for testis loss: clinical observation of 18 cases]. 61
22574373 2012
31
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. 61
22112793 2012
32
Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. 61
21833840 2011
33
Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. 61
21532887 2011
34
Urinary prostate cancer 3 test: toward the age of reason? 61
19586654 2010
35
Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis. 61
23074405 2010
36
The bioactive compounds alpha-chaconine and gallic acid in potato extracts decrease survival and induce apoptosis in LNCaP and PC3 prostate cancer cells. 61
20574921 2010
37
Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. 61
28050174 2009
38
[Molecular markers associated with prostate cancer: 3-nitrotyrosine and genetic and proteic expression of Mn-superoxide dismutasa (Mn-SOD)]. 61
19955594 2009
39
[Prognosis and predictive factors in prostate cancer]. 61
19357018 2009
40
Granulocyte macrophage colony-stimulating factor may modulate the post-transcription pathway of interleukin-6 expression in prostate carcinoma cells. 61
18303206 2008
41
Reduced tumor growth in vivo and increased c-Abl activity in PC3 prostate cancer cells overexpressing the Shb adapter protein. 61
17697368 2007
42
Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. 61
17826523 2007
43
Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study. 61
24683213 2007
44
Intermittent chemotherapy for metastatic hormone refractory prostate cancer. 61
17161610 2007
45
Prostate cancer: local staging at 3-T endorectal MR imaging--early experience. 61
16304091 2006
46
Prostate cancer risk: the significance of differences in age related changes in serum conjugated and unconjugated steroid hormone concentrations between Arab and Caucasian men. 61
16502050 2006
47
[Long term survival results in advanced prostate cancer treated with combined androgen blockade]. 61
16281513 2005
48
Clinical assessment of outcome of prostate cancer (TCP, NTCP). 61
16294903 2005
49
Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. 61
15453805 2004
50
Gene expression in cancer cells is influenced by contact with bone cells in a novel coculture system that models bone metastasis. 61
15346052 2004

Variations for Prostate Cancer, Hereditary, 3

Expression for Prostate Cancer, Hereditary, 3

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 3.

Pathways for Prostate Cancer, Hereditary, 3

GO Terms for Prostate Cancer, Hereditary, 3

Sources for Prostate Cancer, Hereditary, 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....